Jane Street Group LLC Boosts Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Jane Street Group LLC lifted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 122.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 765,475 shares of the company’s stock after acquiring an additional 421,302 shares during the period. Jane Street Group LLC owned approximately 1.12% of Amylyx Pharmaceuticals worth $2,893,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in shares of Amylyx Pharmaceuticals by 91.1% in the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock worth $274,000 after purchasing an additional 40,319 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Amylyx Pharmaceuticals by 144.4% during the third quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock valued at $455,000 after buying an additional 83,048 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after buying an additional 4,883 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Amylyx Pharmaceuticals in the 4th quarter worth about $56,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Amylyx Pharmaceuticals by 43.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,263,353 shares of the company’s stock worth $4,775,000 after buying an additional 382,608 shares in the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Mizuho upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $3.00 to $7.00 in a research note on Monday, April 7th. Leerink Partnrs raised shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 6th. HC Wainwright increased their price target on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a “buy” rating in a report on Friday, May 9th. Finally, Leerink Partners upgraded Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $10.00 in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $9.67.

Amylyx Pharmaceuticals Trading Down 2.4%

Amylyx Pharmaceuticals stock opened at $4.49 on Wednesday. Amylyx Pharmaceuticals, Inc. has a 12-month low of $1.58 and a 12-month high of $7.27. The firm has a market capitalization of $399.99 million, a price-to-earnings ratio of -1.18 and a beta of -0.60. The firm has a 50 day moving average of $4.09 and a 200 day moving average of $4.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.03. On average, analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Insider Buying and Selling

In related news, Director Bernhardt G. Zeiher bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was purchased at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $37,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Joshua B. Cohen sold 21,490 shares of the firm’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $74,570.30. Following the transaction, the chief executive officer now directly owns 3,355,280 shares of the company’s stock, valued at $11,642,821.60. The trade was a 0.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,980 shares of company stock worth $168,627. 11.70% of the stock is owned by corporate insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.